Abstract: The disclosure is directed to methods and apparatus for the determination, diagnosis, progression and prognosis of kidney disease and mortality associated with kidney disease. The disclosure includes methods for determining renal function, in particular estimating glomerular filtration rate (GFR), in an animal. GFR can be useful in the diagnosis and treatment of kidney disease or dysfunction. In various aspects, the disclosure is directed to the use of free symmetrical dimethylarginine (SDMA) and creatinine in blood samples from animals, in particular cats and dogs, to determine glomerular filtration rate and kidney disease.

Abstract: The invention is directed to antibody compositions that specifically bind to polycyclic aromatic hydrocarbons (PAHs) and kits encompassing the same.

Abstract: An immunoassay composition includes at least (i) an amphipol and (ii) a (meth)acrylate monomer-based amphoteric copolymer, some of said monomers including a phosphorylcholine group. The composition is useful in particular as a stabilizer and/or blocking agent.

Abstract: Grids comprising a coating modified with one or more capture agents and a deactivating agent are disclosed. Methods of using such grids in connection with suitable microscopy techniques, such as for determining the structure of target compounds including proteins, are also disclosed.

Abstract: The present invention relates to the use of 1,25-dihydroxyvitamin D values in ratio with PTH as a prognostic biomarker. More particularly, the present invention relates to a method for predicting or stratifying the risk of worsening renal function (WRF) in a patient at risk of renal injury or affected by renal injury. Levels of 1,25-dihydroxyvitamin D (1,25(OH)2D) are measured in a biological sample and taken together with parathyroid hormone (PTH) levels to provide a ratio indicative of the risk of worsening renal function.

Abstract: The present invention provides compositions and methods for capture and identification of the cellular targets of a bioactive agent. In particular, provided herein are bioactive agents tethered to capture ligand, cellular targets (optionally tagged with a reporter), capture proteins (optionally present as capture fusions), surfaces (e.g., displaying, capture ligands, capture proteins, or capture fusions), and methods of capturing and identifying the cellular targets of a bioactive agent therewith.

Abstract: Provided herein are immunofluorescence assays that do not use an intensely colored lipophilic dye, and that result in a significant reduction of fluorescence due to aldehyde fixation, collagen, elastin, and/or red blood cells. In certain embodiments of the present invention, a two-step treatment of the tissue is contemplated that leads to the incorporation of reduced heteropoly acids or salts thereof (e.g., phosphomolybdate species) in the tissue. This reagent binds tightly to hydrophilic regions of the tissue and effectively quenches the fluorescence in those regions. In doing so, the overall signal-to-noise ratio for the immunofluorescence assay is increased.

Abstract: An inorganic nanoparticle is provided (step A) having the size of the aggregate of the protein misfolding disease. Free amino groups or free carboxyl groups are formed (step B) on the surface of the nanoparticle (for functionalizing the nanoparticle surface into an amine- or carboxy-functionalized nanoparticle. Maleinimido spacer carboxylic acid is bound to the free amino groups in step (B). Or, free carboxyl groups in step (B) are converted into NHS esters. Monomers of the protein aggregate are bound i) to the maleinimido spacer carboxylic acids by way of a sulfhydryl group at the free end of the monomers, or ii) to the NHS esters by way of the amino group at the free end of the monomer. A standard is provided for use in the detection of protein aggregates occurring with protein misfolding diseases.

Abstract: Disclosed are methods of detecting one or more analytes in a sample by: (1) associating the sample with a surface that includes an analyte binding agent to result in the immobilization of the analytes on the surface; (2) contacting the analyte with a composition that includes at least one phosphor compound with an affinity for the analyte; (3) formation of immobilized analyte binding agent-analyte-phosphor complexes on the surface; (4) separating unbound phosphor compounds from the immobilized complexes; (5) detecting a presence or absence of a luminescence signal from the immobilized complexes; and (6) correlating the luminescence signal to the presence or absence of the analyte in the sample. The phosphor compound may include (Sr1-?Ba?)2-j-kMgSi2O7:EujDyk, (Sr1-?Ba?)2-xMgSi2O7:Eu2+Dy3+, (Sr1-?Ba?)2MgSi2O7:Eu2+Dy3+, (Sr1-?Ba?)2-xMgSi2O7:Eu2+, and combinations thereof.

Abstract: Provided is a method for measuring amyloid precursor protein (APP) cleavage peptides including amyloid beta (A?) peptides.

Abstract: Provided herein are methods of using photocleavable labels for multiplex and serial antigen detection. The methods comprise detecting the presence of photocleavable labels, which are conjugated through functional linkers to antigen-binding complexes, which in turn non-covalently bind to antigens. The presence of a photocleavable label is indicative of the presence of an antigen specifically or selectively bound by an antigen-binding complex. Also provided are apparatuses for using photocleavable labels for multiplex and serial antigen detection.

Abstract: The invention relates to functional lipid constructs and their use in diagnostic and therapeutic applications, including serodiagnosis, where the functional moiety is carbohydrate, peptide, chemically reactive group, conjugator or fluorophore.

Abstract: The invention relates to a method of identifying molecules which inhibit the virulence machinery of Pseudomonas aeruginosa, to a device for identifying a molecule which inhibits the virulence machinery of Pseudomonas aeruginosa, to novel compounds which inhibit the virulence machinery of Pseudomonas aeruginosa, to compounds for use for preventing and/or treating a pathogenic infection caused by Pseudomonas aeruginosa and also to pharmaceutical compositions for preventing and/or treating a pathogenic infection caused by Pseudomonas aeruginosa.

Abstract: The disclosure relates to compositions for use in assays, the compositions comprising at least one latent fluorophore including at least one enzyme-reactive quenching group and a conjugative group; and a support connectable to the latent fluorophore by the conjugative group. The disclosure further relates to methods of measuring the presence and/or concentration of an analyte, as well as methods of measuring the relative activity of at least two enzymes.

Abstract: The invention is directed to a Method for detecting a target moiety in a sample of biological specimens by: a) providing at least one conjugate with the general formula (I) An-P-Bm-Cq-Xo??(I) ?with A: antigen recognizing moiety; P: enzymatically degradable spacer; B: first binding moiety C second binding moiety X: detection moiety; n, m, q, o integers between 1 and 100, wherein B and C are non-covalently bound to each other and A and B are covalently bound to P b) labelling the target moiety recognized by the antigen recognizing moiety A with at least one conjugate c) detecting the labelled target moiety via detecting moiety X d) cleaving Cq-Xo by disrupting the non-covalent bond between Bm and Cq from the labelled target moiety e) cleaving the binding moiety Bm from the labelled target moiety by enzymatically degrading spacer P. The method is useful to identify target moieties on the biological specimens.

Abstract: Disclosed is an immunochromatographic test strip by which the influences by the interfering substances in the immunochromatography method, contained in test samples, are reduced, so that it enables to accurately and specifically measure a test substance in a test sample irrespective of the amount of the test sample supplied to the assay, and to provide an immunochromatography method using the immunochromatographic test strip. The immunochromatographic test strip includes, in the order from upstream, a sample pad, a labeled substance region, a detection region and an absorption band, wherein a polymer(s) in which hydrophobic cyclic monomer(s) having an ionic functional group(s) is/are polymerized is impregnated at a region(s) upstream of the labeled substance region.

Abstract: Provided herein are methods for determining the efficacy of treatment for polycystic kidney disease (PKD) in a patient, diagnosing PKD in a patient, staging PKD in a patient, and monitoring PKD in a patient. These methods include determining a single or multiple levels of one or more markers selected from the group of Proliferating Cell Nuclear Antigen (PCNA), cyclin D1, cyclin D3, MAPKERK kinase 1 (MEK), ribosomal protein S6 (S6), phosphorylated ribosomal protein S6 (pS6), extracellular signal-regulated kinase (ERK), phosphorylated extracellular signal-regulated kinase (pERK), protein kinase B (Akt), phosphorylated protein kinase B (pAkt), caspase-2, total S6, and retinoblastoma binding protein (RBBP). Also provided are kits that include at least three antibodies that specifically bind to one or more of these markers.

Abstract: Compounds of general formula I wherein Fc and Fc? may be the same or different and are substituted ferrocenyl moieties having at least one ring substituent selected from sulfur-containing groups, phosphorus-containing groups, iodo, chloro, silyl, fluoroalkyl groups containing two or more fluorine atoms, heteroaryl, substituted phenyl, and cyano, wherein if present as sole substituent the cyano group is located on the proximal cyclopentadienyl ring; X is a spacer, Y is a spacer, Z is a spacer; and R is a linker group. Compound I may be used to make labelled substrates, functionalised compounds for making labelled substrates and may be used as labels in an electrochemical assay.

Abstract: Compounds of general formula I are used as labels in an electrochemical assay: (I) in which: Fc and Fc? are substituted or unsubstituted ferrocenyl moieties, X is a C1 to C6 alkylene chain which is optionally interrupted by —O— or —NH—; Y is a C1 to C6 alkylene chain which is optionally interrupted by —O— or —NH—; Z is a C1 to C12 alkylene chain which may optionally be substituted and/or may optionally be interrupted by —O—, —S—, cycloalkyl, —CO—, —CON R1—, —NR1CO— or —NR1— in which R1 represents hydrogen or C1 to C4 alkyl; and R is a linker group. Compounds I are used to make labelled substrates, as well as functionalised compounds for making the labelled substrates.

Abstract: Antibodies, immunoassay methods and kits for the detection and determination of 3,4,-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide and 3,4,-dichloro-N-[2-(methylamino)cyclohexyl]-N-methylbenzamide, as well as the precursory immunogens, are described.